Mesa Laboratories (MLAB)
Supplies sterilization, biopharma, calibration, and clinical-genomics tools for regulated health markets.
$134.63
After-hours close−0.02 (−0.01%)
At close$134.65(+2.11%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 90.80% | 5.08M shares | |
|---|---|---|---|
| 161 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.90% | 162.3K shares | |
| 11 holders · as of Aug 17, 2026 | |||
| Other | ≈ 6.30% | 352.3K shares | |
| remainder | |||
5.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
161 holders · 5.08M shares · 22 new positions · 95 increased · 38 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Long Path Partners LP | 477.1K | 8.53% | +71.5K | Jul 31, 2026 |
| BlackRock, Inc. | 440.6K | 7.87% | +46.7K | Aug 7, 2026 |
| Boston Partners | 265.1K | 4.74% | −3.6K | Aug 4, 2026 |
| Vanguard Capital Management LLC | 237.5K | 4.24% | +4.8K | Aug 13, 2026 |
| AQR Capital Management LLC | 203.7K | 3.64% | +33.2K | Aug 14, 2026 |
| Ranger Investment Management, L.P. | 174.0K | 3.11% | −28.9K | Aug 13, 2026 |
| Morgan Stanley | 157.0K | 2.81% | −5.1K | Aug 13, 2026 |
| Diamond Hill Capital Management Inc | 155.8K | 2.78% | +469 | Aug 6, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Conestoga Capital Advisors | 11.38% | 618.1K | 13G | Jan 10, 2025 |
| Long Path Smaller Companies Fund, LP | 7.30% | 405.6K | 13G | Apr 15, 2026 |
| BlackRock, Inc. | 6.90% | 378.9K | 13G | Oct 2, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | John James Sullivandirector | Sale | 7,093 | $112.80 | 17,834 |
| Aug 13, 2026 | Siddhartha Kadiaofficer: President and CEO | Purchase | 7,093 | $112.80 | 7,093 |
| Aug 13, 2026 | R. Tony Tripenydirector | Purchase | 900 | $113.69 | 6,298 |
| Jun 22, 2026 | John Sakysofficer: CFO | Sale | 2,827 | $89.50 | 19,785 |
| Jun 22, 2026 | Brian David Archboldofficer: SVP Operations | Sale | 2,516 | $89.50 | 6,377 |
| Jun 22, 2026 | Lyndsey Elizabeth Crennenofficer: CAO | Sale | 442 | $89.50 | 2,020 |
| Jun 16, 2026 | John Sakysofficer: CFO | Sale | 1,223 | $101.27 | 16,538 |
| Jun 16, 2026 | Lyndsey Elizabeth Crennenofficer: CAO | Sale | 118 | $101.27 | 1,473 |
| Jun 16, 2026 | Brian David Archboldofficer: SVP Operations | Sale | 1,151 | $101.27 | 3,710 |
| Mar 10, 2026 | R. Tony Tripenydirector | Purchase | 1,315 | $76.00 | 5,398 |
House and Senate disclosures
Not reported.